Literature DB >> 22907284

Previous outpatient antibiotic use in patients admitted to hospital for COPD exacerbations: room for improvement.

M Miravitlles1, J J Soler-Cataluña, F Baranda, P Cordero, J-V Greses, C de la Roza.   

Abstract

PURPOSE: Several studies have analyzed factors associated to hospitalization in chronic obstructive pulmonary disease (COPD) patients. However, data are lacking on the quality of treatment received by patients prior to hospital admission. The present study analyzed how often patients requiring hospitalization for a COPD exacerbation had received previous treatment for the exacerbation, particularly antibiotics.
METHODS: This was a multicenter, cross-sectional, observational study conducted in 30 Spanish hospitals among COPD patients aged >40 years who were hospitalized for an acute exacerbation. Patients were grouped according to whether or not they had received treatment prior to admission and, subsequently, according to whether or not they had received antibiotics. Patient eligibility for antibiotic therapy was assessed using both national and European guidelines.
RESULTS: The study population consisted of 298 patients, of which 277 (93 %) were men, with a mean [standard deviation (SD)] age of 69.1 (9.5) years. One hundred and thirty-three patients (45 %) had received treatment prior to admission; among these, 76/133 (57 %) had received antibiotic therapy. However, 81-91 % of these patients fulfilled criteria for this therapy. Antibiotic use was significantly associated with yellow or green-yellow sputum prior to the exacerbation, a higher number of exacerbations in the previous year, more visits to emergency departments, and bronchiectasis. On the other hand, 10-20 % of patients who did receive antibiotics were not eligible for this therapy according to guidelines.
CONCLUSIONS: This study demonstrates a low rate of previous outpatient treatment and antibiotic use among patients with a COPD exacerbation requiring hospital admission.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22907284     DOI: 10.1007/s15010-012-0316-8

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  42 in total

1.  Antibiotic resistance really starts to hurt.

Authors:  C Ruef
Journal:  Infection       Date:  2011-12       Impact factor: 3.553

2.  Evaluation of potential biomarkers for the discrimination of bacterial and viral infections.

Authors:  P Chalupa; O Beran; H Herwald; N Kaspříková; M Holub
Journal:  Infection       Date:  2011-07-01       Impact factor: 3.553

3.  Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD.

Authors:  S G Adams; J Melo; M Luther; A Anzueto
Journal:  Chest       Date:  2000-05       Impact factor: 9.410

4.  Patients hospitalized for COPD have a high prevalence of modifiable risk factors for exacerbation (EFRAM study).

Authors:  J Garcia-Aymerich; E Barreiro; E Farrero; R M Marrades; J Morera; J M Antó
Journal:  Eur Respir J       Date:  2000-12       Impact factor: 16.671

Review 5.  Clinical phenotypes of COPD: identification, definition and implications for guidelines.

Authors:  Marc Miravitlles; Myriam Calle; Juan José Soler-Cataluña
Journal:  Arch Bronconeumol       Date:  2011-12-22       Impact factor: 4.872

6.  Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease.

Authors:  J J Soler-Cataluña; M A Martínez-García; P Román Sánchez; E Salcedo; M Navarro; R Ochando
Journal:  Thorax       Date:  2005-07-29       Impact factor: 9.139

7.  Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. EOLO Group. Estudio Observacional de la Limitación Obstructiva al Flujo aEreo.

Authors:  M Miravitlles; C Mayordomo; M Artés; L Sánchez-Agudo; F Nicolau; J L Segú
Journal:  Respir Med       Date:  1999-03       Impact factor: 3.415

8.  Efficacy of moxifloxacin in the treatment of bronchial colonisation in COPD.

Authors:  M Miravitlles; A Marín; E Monsó; S Vilà; C de la Roza; R Hervás; C Esquinas; M García; L Millares; J Morera; A Torres
Journal:  Eur Respir J       Date:  2009-04-22       Impact factor: 16.671

9.  Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort.

Authors:  Lisa Langsetmo; Robert W Platt; Pierre Ernst; Jean Bourbeau
Journal:  Am J Respir Crit Care Med       Date:  2007-11-29       Impact factor: 21.405

10.  Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial.

Authors:  Sanjay Sethi; Paul W Jones; Marlize Schmitt Theron; Marc Miravitlles; Ethan Rubinstein; Jadwiga A Wedzicha; Robert Wilson
Journal:  Respir Res       Date:  2010-01-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.